Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer

Journal of Urology

Volumn 173, Issue 2, 2005, Pages 441-

  Yamagishi, Takuya ^a   Uemura, Hiroji ^a   Nakaigawa, Noboru ^a   Noguchi, Kazumi ^a   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Angiotensin II, prostatic neoplasms; Hormones

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BICALUTAMIDE; CANDESARTAN; DEXAMETHASONE; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BONE METASTASIS; CASE REPORT; HUMAN; LEG PAIN; MALE; METASTASIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SPINAL CORD METASTASIS;

EID: 12544251001     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000148855.17830.97     Document Type: Article

References (3)

1. Uemura, H., Ishiguro, H., Nakaigawa, N., Nagashima, Y., Miyoshi, Y., Fujinami, K. et al: Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther, 2: 1139, 2003
2. Fujita, M., Hayashi, I., Yamashina, S., Itoman, M. and Majima, M.: Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun, 294: 441, 2002
3. Egami, K, Murohara, T., Shimada, T., Sasaki, K, Shintani, S., Sugaya, T. et al: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest, 112: 67, 2003